Avid Bioservices Inc (CDMO)

[exwannabe]

Those who are new to PPHM are only hearing about Cotara in relation to GMB,but Cotara can be used on all solid tumors.

The other radio-MABs (Zevalin and Bexxar) have been commercial flops despite (at least for Zev) having some quite good clinical data backing it.

Over almost 10 years, the uptake for these has been very slow. Many excuses, but one that stands out is that the fear of the MABs accumulating in the lymph system could cause such damage as to make further treatment challenging.

I have to wonder if the reason Cotara went after brain cancer was to take advantage of the blood brain barrier. This would seriously limit the off-targert radiation.

As far as "arm"-ing with other agents, the conjugation race has been on for a while. It is not trivial to do such (even if the MAB itself is already proven). The linkers are complicated because they need to be stable while circulating, but release when internalized (IMGN has claims to be able link to non-intenalized MAbs, but no proof yet).

If PPHM wanted to do such, it needs to license (in or out) or partner, it is not somethng that just happens.

BTW, the conjugation with radioisomers is vastly easier as the isotope will be effective by just being in the vicinity.

P.S. to KT. For chemoes, the agents used to conjugate are not SOC. They use stronger molecules that are more effective killers, but too toxic for general use.